IO Biotech, Inc. (NASDAQ:IOBT) is among the top 11 low price, high volume stocks to buy, with H.C. Wainwright maintaining a Buy rating and $14 price target. The company’s pivotal phase 3 trial for Cylembio therapy showed improvement in progression-free survival for advanced melanoma patients.

IO Biotech plans to submit a biologics license application for Cylembio to the FDA by the end of 2025. The company’s pipeline includes promising phase 2 trials for other cancer types, with data expected soon. Analyst Emily Bodnar remains positive on the company’s development and sees potential in addressing unmet medical needs in oncology.

Read more at Yahoo Finance: H.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14